UroGen Pharma candidate products are based on two proprietary platform technologies:
RTGel™ – proprietary reverse thermal gelation hydrogel for local administration of sustained release formulations of chemotherapy.
Based on this technology, UroGen Pharma developed Mitogel™, a novel Mitomycin C formulation, for the treatment of upper tract urothelial carcinoma (UTUC), VesiGel™ a novel high-dose Mitomycin C formulation for the treatment of certain forms of Non-Muscle Invasive Bladder Cancer (NMIBC) and BotuGel™, a formulation of botulinum toxin, for the treatment of Overactive Bladder (OAB) and Interstitial Cystitis (IC) (BotuGel has been recently licensed to Allergan).
Immunotherapy – locally triggering the innate immune system via unique formulation of immune modulating drugs for intravesical use.
Based on this technology, UroGen Pharma is developing a unique immune-modulation drug candidate, Vesimune™, based on Toll like receptors 7 (TLR7) stimulators, for the treatment of Carcinoma in Situ (CIS) of the bladder.